Cargando…
Small change, big difference: A promising praziquantel derivative designated P96 with broad-spectrum antischistosomal activity for chemotherapy of schistosomiasis japonica
BACKGROUND: Praziquantel (PZQ) has been the first line antischistosomal drug for all species of Schistosoma, and the only available drug for schistosomiasis japonica, without any alternative drugs since the 1980s. However, PZQ cannot prevent reinfection, and cannot cure schistosomiasis thoroughly be...
Autores principales: | Xu, Jing, Dong, Lan-Lan, Sun, Huan, Huang, Ping, Zhang, Run-Ze, Wang, Xin-Yi, Sun, De-Qun, Xia, Chao-Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353801/ https://www.ncbi.nlm.nih.gov/pubmed/37410790 http://dx.doi.org/10.1371/journal.pntd.0011215 |
Ejemplares similares
-
An Artemisinin Derivative of Praziquantel as an Orally Active Antischistosomal Agent
por: Dong, Lanlan, et al.
Publicado: (2014) -
Development of Praziquantel sulphonamide derivatives as antischistosomal drugs
por: Angeli, Andrea, et al.
Publicado: (2022) -
Antischistosomal and anti-inflammatory activity of garlic and allicin compared with that of praziquantel in vivo
por: Metwally, Dina M., et al.
Publicado: (2018) -
A diagnostic challenge for schistosomiasis japonica in China: consequences on praziquantel-based morbidity control
por: Zhou, Yi-biao, et al.
Publicado: (2011) -
In vivo assessment of the antischistosomal activity of curcumin loaded nanoparticles versus praziquantel in the treatment of Schistosoma mansoni
por: Mokbel, Kamal El-Din M., et al.
Publicado: (2020)